CX Institutional Grows Holdings in Johnson & Johnson $JNJ

Key Points

• CX Institutional more than doubled its Johnson & Johnson stake by 113.4% in the third quarter, adding 34,418 shares for a total holding valued at approximately $17.15 million. Institutional investors collectively own 69.55% of J&J.
• J&J reported quarterly adjusted EPS of $2.90 and revenue of $25.31 billion, exceeding analyst estimates, while revenue increased 6.6% year over year. The company also pays a quarterly dividend of $1.34 per share, representing a 2.1% yield.
• Positive pipeline updates, including durable psoriasis results for ICOTYDE, support future growth, but Stelara biosimilar competition remains a key risk. Analysts maintain a “Moderate Buy” consensus with an average price target of $275.87, above the reported trading price of $255.94.

CX Institutional boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 113.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 64,782 shares of the company's stock after buying an additional 34,418 shares during the period. CX Institutional's holdings in Johnson & Johnson were worth $17,150,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Auto Owners Insurance Co boosted its stake in shares of Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock worth $1,436,633,000 after purchasing an additional 69,108,368 shares during the period. Wellington Management Group LLP lifted its stake in Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Johnson & Johnson by 8.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,275,937 shares of the company's stock worth $3,575,255,000 after purchasing an additional 1,376,828 shares during the last quarter. Deutsche Bank AG boosted its position in shares of Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company's stock valued at $3,977,506,000 after buying an additional 1,225,676 shares during the period. Finally, Amundi grew its stake in shares of Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company's stock valued at $3,277,163,000 after buying an additional 2,001,139 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Vanessa Broadhurst sold 23,054 shares of the business's stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 87,569 shares of company stock worth $23,064,544. Company insiders own 0.16% of the company's stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: ICOTYDE delivers durable psoriasis results: New Phase 3 ICONIC-TOTAL data showed sustained skin clearance through two years. At Week 112, 70% of patients achieved clear or almost clear skin, while complete clearance reached 89% for genital psoriasis and 60% for scalp psoriasis, with no new safety concerns reported. The results support ICOTYDE as a potential important first-line systemic treatment and strengthen J&J’s immunology pipeline. J&J ICOTYDE psoriasis data
• Positive Sentiment: Innovative Medicine growth remains a key offset: Analysts expect oncology products and newer launches to drive another quarter of growth, helping counter revenue erosion from Stelara biosimilars. This supports the investment case that J&J can replace lost exclusivity revenue with newer products. Innovative Medicine Q3 growth drivers
• Positive Sentiment: IMAAVY adds pipeline support: New data in generalized myasthenia gravis gives investors additional evidence that J&J’s immunology portfolio could provide future growth beyond current blockbuster medicines. IMAAVY data update
• Neutral Sentiment: J&J continues to receive favorable valuation commentary and analyst support after a strong one-year advance, but its approximately 30-times earnings valuation leaves less room for disappointment.
• Negative Sentiment: Stelara biosimilar pressure remains the central risk: The expected decline in Stelara sales is weighing on near-term growth comparisons and may be contributing to investor caution despite positive pipeline news.

Johnson & Johnson Trading Down 1.1%

NYSE:JNJ traded down $2.72 during midday trading on Friday, hitting $255.94. The stock had a trading volume of 10,250,638 shares, compared to its average volume of 7,993,228. The stock has a 50-day moving average of $266.52 and a 200 day moving average of $248.31. The company has a market capitalization of $616.79 billion, a price-to-earnings ratio of 29.66, a PEG ratio of 2.60 and a beta of 0.21. Johnson & Johnson has a one year low of $182.94 and a one year high of $281.07. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.Johnson & Johnson's revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.54 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is presently 62.11%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company raised their price target on Johnson & Johnson from $272.00 to $282.00 and gave the stock an "overweight" rating in a research note on Monday, August 3rd. Morgan Stanley upped their price objective on Johnson & Johnson from $284.00 to $294.00 and gave the company an "overweight" rating in a research report on Thursday, July 16th. Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research report on Wednesday, July 15th. HSBC boosted their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a research note on Thursday, September 10th. Finally, UBS Group reaffirmed a "buy" rating on shares of Johnson & Johnson in a research note on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $275.87.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.